WINTON GROUP Ltd Buys 58,039 Shares of The Chemours Company $CC

WINTON GROUP Ltd boosted its stake in The Chemours Company (NYSE:CC) by 103.5% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 114,100 shares of the specialty chemicals company’s stock after acquiring an additional 58,039 shares during the quarter. WINTON GROUP Ltd’s holdings in Chemours were worth $1,807,000 as of its most recent SEC filing.

A number of other large investors have also recently added to or reduced their stakes in the company. Russell Investments Group Ltd. lifted its holdings in shares of Chemours by 130.4% in the third quarter. Russell Investments Group Ltd. now owns 126,412 shares of the specialty chemicals company’s stock valued at $2,002,000 after purchasing an additional 71,537 shares in the last quarter. Dynamic Technology Lab Private Ltd bought a new position in shares of Chemours during the third quarter worth about $444,000. Neo Ivy Capital Management acquired a new stake in Chemours in the 3rd quarter valued at approximately $1,477,000. Icon Advisers Inc. Co. lifted its stake in Chemours by 51.1% in the 3rd quarter. Icon Advisers Inc. Co. now owns 659,365 shares of the specialty chemicals company’s stock valued at $10,444,000 after acquiring an additional 223,000 shares in the last quarter. Finally, Barclays PLC boosted its position in Chemours by 175.8% during the 3rd quarter. Barclays PLC now owns 936,284 shares of the specialty chemicals company’s stock worth $14,831,000 after acquiring an additional 596,834 shares during the last quarter. Institutional investors own 76.26% of the company’s stock.

Chemours Stock Performance

NYSE CC opened at $17.76 on Wednesday. The firm has a market capitalization of $2.67 billion, a P/E ratio of -7.16 and a beta of 1.60. The company has a current ratio of 1.78, a quick ratio of 0.85 and a debt-to-equity ratio of 16.33. The firm’s fifty day moving average price is $16.60 and its two-hundred day moving average price is $14.78. The Chemours Company has a 1 year low of $9.13 and a 1 year high of $21.85.

Chemours (NYSE:CC) last issued its earnings results on Thursday, February 19th. The specialty chemicals company reported $0.05 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.01 by $0.04. The company had revenue of $1.33 billion for the quarter, compared to analysts’ expectations of $1.33 billion. Chemours had a negative net margin of 6.41% and a positive return on equity of 41.75%. Chemours’s quarterly revenue was down 2.2% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.09 EPS. As a group, research analysts anticipate that The Chemours Company will post 2.03 EPS for the current year.

Chemours Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, March 13th. Shareholders of record on Friday, February 27th will be given a dividend of $0.0875 per share. The ex-dividend date is Friday, February 27th. This represents a $0.35 annualized dividend and a yield of 2.0%. Chemours’s dividend payout ratio (DPR) is -14.11%.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on CC shares. JPMorgan Chase & Co. lifted their price objective on shares of Chemours from $13.00 to $17.00 and gave the company a “neutral” rating in a report on Monday, February 23rd. The Goldman Sachs Group increased their target price on shares of Chemours from $14.00 to $18.00 and gave the stock a “neutral” rating in a report on Wednesday, February 25th. Morgan Stanley lifted their price target on shares of Chemours from $15.00 to $17.00 and gave the company an “equal weight” rating in a research note on Monday, February 23rd. BMO Capital Markets reduced their price objective on shares of Chemours from $20.00 to $19.00 and set an “outperform” rating for the company in a research note on Monday, February 23rd. Finally, Royal Bank Of Canada reaffirmed an “outperform” rating and issued a $18.00 target price on shares of Chemours in a research report on Friday, January 16th. Five analysts have rated the stock with a Buy rating, five have given a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus price target of $18.40.

Chemours Company Profile

Chemours Company, established in 2015 as a spin-off from E. I. du Pont de Nemours and Company, is a global chemistry organization headquartered in Wilmington, Delaware. Since its formation, Chemours has focused on delivering performance chemicals that help customers lower their carbon footprint, increase energy efficiency and conserve water. The company operates with a commitment to safety, environmental stewardship and innovation.

Chemours’ principal business activities are organized into three core segments.